• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型冠状病毒变异株刺突蛋白突变及抗体研发的研究进展

Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development.

作者信息

Huan Xinkang, Zhan Jiuyu, Gao Hongwei

机构信息

School of Life Science, Ludong University, Yantai, Shandong, China.

出版信息

Front Immunol. 2024 Nov 18;15:1407149. doi: 10.3389/fimmu.2024.1407149. eCollection 2024.

DOI:10.3389/fimmu.2024.1407149
PMID:39624100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11609190/
Abstract

The coronavirus disease 2019 (COVID-19) is a respiratory disease with a very high infectious rate caused by the Severe Acute Respiratory Syndrome Coronavirus-2(SARS-CoV-2). Because SARS-CoV-2 is easy to mutate, the continuous emergence of SARS-CoV-2 variant strains not only enhances the infectivity of the SARS-CoV-2 but also brings great obstacles to the treatment of COVID-19. Neutralizing antibodies have achieved good results in the clinical application of the novel coronavirus pneumonia, which can be used for pre-infection protection and treatment of novel coronavirus patients. This review makes a detailed introduction to the mutation characteristics of SARS-CoV-2, focusing on the molecular mechanism of mutation affecting the infectivity of SARS-CoV-2, and the impact of mutation on monoclonal antibody therapy, providing scientific reference for the prevention of SARS-CoV-2 variant strains and the research and development of antibody drugs.

摘要

2019冠状病毒病（COVID-19）是由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的一种具有很高感染率的呼吸道疾病。由于SARS-CoV-2易于变异，SARS-CoV-2变异株的不断出现不仅增强了SARS-CoV-2的传染性，也给COVID-19的治疗带来了巨大障碍。中和抗体在新型冠状病毒肺炎的临床应用中取得了良好效果，可用于新型冠状病毒感染前的预防及新型冠状病毒患者的治疗。本文详细介绍了SARS-CoV-2的突变特征，重点阐述了突变影响SARS-CoV-2传染性的分子机制以及突变对单克隆抗体治疗的影响，为预防SARS-CoV-2变异株及抗体药物研发提供科学参考。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/5d451b62d57c/fimmu-15-1407149-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/6cedd0b0f68a/fimmu-15-1407149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/15f4e183eac8/fimmu-15-1407149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/b8337fb731a8/fimmu-15-1407149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/eab456dd6371/fimmu-15-1407149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/4f4594e8ea99/fimmu-15-1407149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/983ea974b9c5/fimmu-15-1407149-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/165bdea36c70/fimmu-15-1407149-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/24db9dfaf41a/fimmu-15-1407149-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/5d451b62d57c/fimmu-15-1407149-g009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/6cedd0b0f68a/fimmu-15-1407149-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/15f4e183eac8/fimmu-15-1407149-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/b8337fb731a8/fimmu-15-1407149-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/eab456dd6371/fimmu-15-1407149-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/4f4594e8ea99/fimmu-15-1407149-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/983ea974b9c5/fimmu-15-1407149-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/165bdea36c70/fimmu-15-1407149-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/24db9dfaf41a/fimmu-15-1407149-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/53f4/11609190/5d451b62d57c/fimmu-15-1407149-g009.jpg

相似文献

1
Research progress of spike protein mutation of SARS-CoV-2 mutant strain and antibody development.新型冠状病毒变异株刺突蛋白突变及抗体研发的研究进展
Front Immunol. 2024 Nov 18;15:1407149. doi: 10.3389/fimmu.2024.1407149. eCollection 2024.
2
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.通过 SARS-CoV-2 刺突蛋白变体逃避中和抗体。
Elife. 2020 Oct 28;9:e61312. doi: 10.7554/eLife.61312.
3
Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.MW06 是一种人源单克隆抗体，对 SARS-CoV-2 和 SARS-CoV 均具有交叉中和活性。
MAbs. 2021 Jan-Dec;13(1):1953683. doi: 10.1080/19420862.2021.1953683.
4
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain.人类针对 SARS-CoV-2 刺突蛋白受体结合域的中和抗体的结构基础。
Microbiol Spectr. 2021 Oct 31;9(2):e0135221. doi: 10.1128/Spectrum.01352-21. Epub 2021 Oct 13.
5
Antibody cocktail effective against variants of SARS-CoV-2.抗体鸡尾酒疗法有效对抗多种 SARS-CoV-2 变异株。
J Biomed Sci. 2021 Nov 23;28(1):80. doi: 10.1186/s12929-021-00777-9.
6
Structural Analysis of Neutralizing Epitopes of the SARS-CoV-2 Spike to Guide Therapy and Vaccine Design Strategies.结构分析 SARS-CoV-2 刺突蛋白的中和表位以指导治疗和疫苗设计策略。
Viruses. 2021 Jan 19;13(1):134. doi: 10.3390/v13010134.
7
The emergence of SARS-CoV-2 variants threatens to decrease the efficacy of neutralizing antibodies and vaccines.SARS-CoV-2 变异株的出现威胁到中和抗体和疫苗的效力。
Biochem Soc Trans. 2021 Dec 17;49(6):2879-2890. doi: 10.1042/BST20210859.
8
Sensitivity of two SARS-CoV-2 variants with spike protein mutations to neutralising antibodies.两种带有刺突蛋白突变的 SARS-CoV-2 变异株对中和抗体的敏感性。
Virus Genes. 2021 Dec;57(6):502-509. doi: 10.1007/s11262-021-01871-8. Epub 2021 Oct 4.
9
In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains.体内单克隆抗体对 SARS-CoV-2 变异株的疗效。
Nature. 2021 Aug;596(7870):103-108. doi: 10.1038/s41586-021-03720-y. Epub 2021 Jun 21.
10
Neutralizing SARS-CoV-2.中和 SARS-CoV-2
Elife. 2020 Dec 15;9:e64496. doi: 10.7554/eLife.64496.

本文引用的文献

1
Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants.严重急性呼吸综合征冠状病毒2（SARS-CoV-2）KP.3、LB.1和KP.2.3变体的病毒学特征
Lancet Infect Dis. 2024 Aug;24(8):e482-e483. doi: 10.1016/S1473-3099(24)00415-8. Epub 2024 Jun 27.
2
Distinct patterns of SARS-CoV-2 BA.2.87.1 and JN.1 variants in immune evasion, antigenicity, and cell-cell fusion.SARS-CoV-2 BA.2.87.1 和 JN.1 变体在免疫逃逸、抗原性和细胞间融合方面的独特模式。
mBio. 2024 May 8;15(5):e0075124. doi: 10.1128/mbio.00751-24. Epub 2024 Apr 9.
3
Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies.
二聚体受体结合域亚单位疫苗和 41 个人源单克隆抗体对 EG.5、EG.5.1、BA.2.86 和 JN.1 的中和作用。
Med. 2024 May 10;5(5):401-413.e4. doi: 10.1016/j.medj.2024.03.006. Epub 2024 Apr 3.
4
Virological characteristics of the SARS-CoV-2 JN.1 variant.严重急性呼吸综合征冠状病毒2 JN.1变体的病毒学特征。
Lancet Infect Dis. 2024 Feb;24(2):e82. doi: 10.1016/S1473-3099(23)00813-7. Epub 2024 Jan 3.
5
Distinctive Combinations of RBD Mutations Contribute to Antibody Evasion in the Case of the SARS-CoV-2 Beta Variant.SARS-CoV-2 贝塔变异株中 RBD 突变的独特组合导致抗体逃逸。
J Microbiol Biotechnol. 2023 Dec 28;33(12):1587-1295. doi: 10.4014/jmb.2308.08020. Epub 2023 Nov 3.
6
In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1.抗病毒药物和单克隆抗体对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）奥密克戎谱系XBB.1.9.1、XBB.1.9.3、XBB.1.5、XBB.1.16、XBB.2.4、BQ.1.1.45、CH.1.1和CL.1的体外疗效
Vaccines (Basel). 2023 Sep 28;11(10):1533. doi: 10.3390/vaccines11101533.
7
Structure, dynamics and free energy studies on the effect of point mutations on SARS-CoV-2 spike protein binding with ACE2 receptor.结构、动力学及点突变对 SARS-CoV-2 刺突蛋白与 ACE2 受体结合影响的自由能研究。
PLoS One. 2023 Oct 5;18(10):e0289432. doi: 10.1371/journal.pone.0289432. eCollection 2023.
8
Probing conformational landscapes of binding and allostery in the SARS-CoV-2 omicron variant complexes using microsecond atomistic simulations and perturbation-based profiling approaches: hidden role of omicron mutations as modulators of allosteric signaling and epistatic relationships.使用微秒原子模拟和基于扰动的剖析方法探究 SARS-CoV-2 奥密克戎变体复合物中的结合和变构构象景观：奥密克戎突变作为变构信号和上位关系调节剂的隐藏作用。
Phys Chem Chem Phys. 2023 Aug 16;25(32):21245-21266. doi: 10.1039/d3cp02042h.
9
Structural Basis for the Enhanced Infectivity and Immune Evasion of Omicron Subvariants.结构基础：奥密克戎亚变体增强的传染性和免疫逃避能力。
Viruses. 2023 Jun 20;15(6):1398. doi: 10.3390/v15061398.
10
Divergent mutations of Delta and Omicron variants: key players behind differential viral attributes across the COVID-19 waves.德尔塔和奥密克戎变体的不同突变：新冠疫情各波次中病毒不同属性背后的关键因素。
Virusdisease. 2023 May 10;34(2):1-14. doi: 10.1007/s13337-023-00823-0.